-
Je něco špatně v tomto záznamu ?
structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor
J. Hejdánek, K. Radilová, P. Pachl, J. Hodek, A. Machara, J. Weber, P. Řezáčová, J. Konvalinka, M. Kožíšek
Antiviral research.
2021 ;
185 (-) :
104971.
[pub] 20201106
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc21026226
- MeSH
- antivirové látky farmakologie MeSH
- interakční proteinové domény a motivy účinky léků fyziologie MeSH
- krystalizace MeSH
- lidé MeSH
- RNA-dependentní RNA-polymerasa chemie metabolismus MeSH
- vazba proteinů MeSH
- virové proteiny antagonisté a inhibitory chemie metabolismus MeSH
- virus chřipky A, podtyp H1N1 účinky léků enzymologie metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Influenza viruses can cause severe respiratory infections in humans, leading to nearly half a million deaths worldwide each year. Improved antiviral drugs are needed to address the threat of development of novel pandemic strains. Current therapeutic interventions target three key proteins in the viral life cycle: neuraminidase, the M2 channel and RNA-dependent-RNA polymerase. Protein-protein interactions between influenza polymerase subunits are potential new targets for drug development. Using a newly developed assay based on AlphaScreen technology, we screened a peptide panel for protein-protein interaction inhibitors to identify a minimal PB1 subunit-derived peptide that retains high inhibition potential and can be further modified. Here, we present an X-ray structure of the resulting decapeptide bound to the C-terminal domain of PA polymerase subunit from pandemic isolate A/California/07/2009 H1N1 at 1.6 Å resolution and discuss its implications for the design of specific, potent influenza polymerase inhibitors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026226
- 003
- CZ-PrNML
- 005
- 20211026133109.0
- 007
- ta
- 008
- 211013s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.antiviral.2020.104971 $2 doi
- 035 __
- $a (PubMed)33166574
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hejdánek, Jakub $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- 245 10
- $a structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor / $c J. Hejdánek, K. Radilová, P. Pachl, J. Hodek, A. Machara, J. Weber, P. Řezáčová, J. Konvalinka, M. Kožíšek
- 520 9_
- $a Influenza viruses can cause severe respiratory infections in humans, leading to nearly half a million deaths worldwide each year. Improved antiviral drugs are needed to address the threat of development of novel pandemic strains. Current therapeutic interventions target three key proteins in the viral life cycle: neuraminidase, the M2 channel and RNA-dependent-RNA polymerase. Protein-protein interactions between influenza polymerase subunits are potential new targets for drug development. Using a newly developed assay based on AlphaScreen technology, we screened a peptide panel for protein-protein interaction inhibitors to identify a minimal PB1 subunit-derived peptide that retains high inhibition potential and can be further modified. Here, we present an X-ray structure of the resulting decapeptide bound to the C-terminal domain of PA polymerase subunit from pandemic isolate A/California/07/2009 H1N1 at 1.6 Å resolution and discuss its implications for the design of specific, potent influenza polymerase inhibitors.
- 650 _2
- $a antivirové látky $x farmakologie $7 D000998
- 650 _2
- $a krystalizace $7 D003460
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a virus chřipky A, podtyp H1N1 $x účinky léků $x enzymologie $x metabolismus $7 D053118
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a interakční proteinové domény a motivy $x účinky léků $x fyziologie $7 D054730
- 650 _2
- $a RNA-dependentní RNA-polymerasa $x chemie $x metabolismus $7 D012324
- 650 _2
- $a virové proteiny $x antagonisté a inhibitory $x chemie $x metabolismus $7 D014764
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Radilová, Kateřina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660/32, 12108, Prague 2, Czech Republic
- 700 1_
- $a Pachl, Petr $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- 700 1_
- $a Hodek, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- 700 1_
- $a Machara, Aleš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic; Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 12800, Prague 2, Czech Republic
- 700 1_
- $a Weber, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- 700 1_
- $a Řezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic; Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14000, Prague 4, Czech Republic
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic; Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12800, Prague 2, Czech Republic
- 700 1_
- $a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610, Prague 6, Czech Republic. Electronic address: milan.kozisek@uochb.cas.cz
- 773 0_
- $w MED00000480 $t Antiviral research $x 1872-9096 $g Roč. 185, č. - (2021), s. 104971
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33166574 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133115 $b ABA008
- 999 __
- $a ok $b bmc $g 1715053 $s 1146733
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 185 $c - $d 104971 $e 20201106 $i 1872-9096 $m Antiviral research $n Antiviral Res $x MED00000480
- LZP __
- $a Pubmed-20211013
